Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione GPascale IRCCS, Naples, Italy



Survival: 13.7 months
   
Toxicity Grade: 3
   
Treatments: Chemotherapy
   
Drugs:
Country: Italy
   
City/State/Province: Naples
   
Hospital: Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione GPascale IRCCS
   
Journal: Link
   
Date: 4/2015

Description:
Patients:
This phase 2 study involved platinum-resistant or platinum-refractory ovarian cancer patients who had received prior chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 36 patients with a median age of 58 years, while group B had 37 patients with a median age of 56 years.

Treatment:
Patients in group A received chemotherapy with paclitaxel.

Patients in group B received chemotherapy with paclitaxel and biologic therapy with pazopanib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities in group A were of grade 3 and included anemia and fatigue. Grade 2 alopecia and nausea were also reported.

The most severe toxicities in group B were of grade 4 and included neutropenia and gastrointestinal perforation. Grade 3 high blood pressure and diarrhea were also reported.

Results:
The median overall survival in groups A and B was 13.7 and 19.1 months, respectively.

Support:
This study was partially supported by Glaxo Smith Kline (makers of pazopanib).

Correspondence: Dr. Sandro Pignata; email: s.pignata@istitutotumori.na.it

E-mail to a Friend Email Physician More Information